The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


90 milligram(s) Film-coated tablet

Bristol-Myers Squibb Pharma EEIGEU/1/14/939/005-006

Main Information

Trade NameDaklinza
Active SubstancesDeclatasvir dihydrochloride (bms-790052-05)
Strength90 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderBristol-Myers Squibb Pharma EEIG
Licence NumberEU/1/14/939/005-006

Group Information

ATC CodeJ05AP07 Daclatasvir


Withdrawn Date30/08/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back